Human Osteoprotegerin/TNFRSF11B DuoSet ELISA, 15 Plate Summary
No significant interference observed with available related molecules.
Packaging, Storage & Formulations
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Human Osteoprotegerin/TNFRSF11B DuoSet ELISA, 15 Plate
OCIF OCIFMGC29565 OPG OPGtumor necrosis factor receptor superfamily member 11B Osteoclastogenesis inhibitory factor Osteoprotegerin TNFRSF11B TR1 tumor necrosis factor receptor superfamily, member 11b Background
Osteoprotegerin (OPG), also known as OCIF and TNFRSF11B, is a secreted TNF superfamily receptor that regulates bone density. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts, and endothelial cells. OPG functions as a decoy receptor for TRANCE/RANK L and TRAIL. OPG regulates the cell surface expression of TRANCE and its ability to stimulate osteoclastogenesis. Dysregulation of OPG/TRANCE interactions can lead to juvenile Paget’s disease, osteoporosis, bone loss, and vascular calcification.
Customers Who Viewed This Item Also Viewed...
Species: Av, Hu, Mu, Rt
Applications: CyTOF-ready, Flow-CS, Flow, IHC, IHC-P, WB
Species: Hu, Rt
Applications: CyTOF-ready, ICC, IHC, ICFlow
Applications: IHC, WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P
Species: Ca, Hu, Mu, Po, Pm, Rt(-)
Applications: Dual ISH-IHC, ICC/IF, IHC, IHC-Fr, IHC-P, IP, KO, PLA, WB
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, IHC, Neut, WB
Applications: ELISA, AP, PA, WB
Applications: Flow, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu, Mu
Applications: IHC, IHC-P, WB
Species: Hu, Mu, Rt
Applications: ELISA, S-ELISA, WB
Applications: IHC, IHC-P
Publications for Osteoprotegerin/TNFRSF11B (DY805)(82)
We have publications tested in 2 confirmed species: Human, Mouse.
We have publications tested in 1 application: ELISA Capture.
Submit a Publication
Filter By Application
Filter By Species
Showing Publications 1 -
Show All 82 Publications.
Publications using DY805
KEC Blokland, M Nizamoglu, H Habibie, T Borghuis, M Schuliga, BN Melgert, DA Knight, CA Brandsma, SD Pouwels, JK Burgess Substrate stiffness engineered to replicate disease conditions influence senescence and fibrotic responses in primary lung fibroblasts Frontiers in Pharmacology, 2022-11-03;13(0):989169. 2022-11-03 [PMID: 36408252] (Human)
T Nicholson, L Davis, ET Davis, M Newton Ede, A Scott, SW Jones e-Cigarette Vapour Condensate Reduces Viability and Impairs Function of Human Osteoblasts, in Part, via a Nicotine Dependent Mechanism Toxics, 2022-08-28;10(9):. 2022-08-28 [PMID: 36136470] (Human)
R Galla, S Ruga, S Aprile, S Ferrari, A Brovero, G Grosa, C Molinari, F Uberti New Hyaluronic Acid from Plant Origin to Improve Joint Protection-An In Vitro Study International Journal of Molecular Sciences, 2022-07-23;23(15):. 2022-07-23 [PMID: 35897688] (Human)
J Jiang, L Röper, S Alageel, U Dornseifer, AF Schilling, E Hadjipanay, HG Machens, P Moog Hypoxia Preconditioned Serum (HPS) Promotes Osteoblast Proliferation, Migration and Matrix Deposition Oncogene, 2022-07-07;10(7):. 2022-07-07 [PMID: 35884936] (Human)
HJ Kim, MS Park, A Joo, S Kang, S Eum, Y Chang, TJ Song Plasma osteoprotegerin level is associated with hemorrhagic transformation in stroke patients who underwent endovascular thrombectomy Clinical neurology and neurosurgery, 2022-05-25;219(0):107305. 2022-05-25 [PMID: 35653867] (Human)
MS Park, JH Park, A Joo, Y Chang, TJ Song The association of plasma osteoprotegerin levels and functional outcomes post endovascular thrombectomy in acute ischemic stroke patients: a retrospective observational study PeerJ, 2022-05-03;10(0):e13327. 2022-05-03 [PMID: 35529501] (Human)
S Passaponti, L Ermini, G Acconci, FM Severi, R Romagnoli, S Cutrupi, M Clerico, G Guerrera, F Ietta Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta Cells, 2022-04-15;11(8):. 2022-04-15 [PMID: 35456036] (Human)
S Hinkelmann, AH Springwald, S Schulze, U Hempel, F Mitrach, C Wölk, MC Hacker, M Schulz-Sie Mineralizing Gelatin Microparticles as Cell Carrier and Drug Delivery System for siRNA for Bone Tissue Engineering Pharmaceutics, 2022-02-28;14(3):. 2022-02-28 [PMID: 35335924] (Human)
JW Kennedy, PM Tsimbouri, P Campsie, S Sood, PG Childs, S Reid, PS Young, DRM Meek, CS Goodyear, MJ Dalby Nanovibrational stimulation inhibits osteoclastogenesis and enhances osteogenesis in co-cultures Scientific Reports, 2021-11-23;11(1):22741. 2021-11-23 [PMID: 34815449] (Human)
MS Park, Y Chang, KH Kim, JH Park, TJ Song Plasma osteoprotegerin levels are associated with the presence and burden of cerebral small vessel disease in patients with acute ischemic stroke Clinical neurology and neurosurgery, 2021-10-28;210(0):107010. 2021-10-28 [PMID: 34752988] (Human)
Show All 82 Publications.
Osteoprotegerin/TNFRSF11B (DY805) (0)
There are no reviews for Osteoprotegerin/TNFRSF11B (DY805).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for Osteoprotegerin/TNFRSF11B (DY805) (0)
Additional Osteoprotegerin/TNFRSF11B Products
Bioinformatics Tool for Osteoprotegerin/TNFRSF11B (DY805)
Discover related pathways, diseases and genes to Osteoprotegerin/TNFRSF11B (DY805). Need help?
Bioinformatics Tool Guide
for instructions on using this tool.
Blogs on Osteoprotegerin/TNFRSF11B